Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-acting amylin analogues for the management of obesity
David S. Mathiesen, Jonatan I. Bagger, Filip K. Knop
Current Opinion in Endocrinology Diabetes and Obesity (2022) Vol. 29, Iss. 2, pp. 183-190
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 720-730
Closed Access | Times Cited: 144
Excess body weight: Novel insights into its roles in obesity comorbidities
Xiang Zhang, Suki Ha, Harry Cheuk-Hay Lau, et al.
Seminars in Cancer Biology (2023) Vol. 92, pp. 16-27
Open Access | Times Cited: 107
Management of diabesity: Current concepts
Maria Michaelidou, Joseph M. Pappachan, Mohammad Sadiq Jeeyavudeen
World Journal of Diabetes (2023) Vol. 14, Iss. 4, pp. 396-411
Open Access | Times Cited: 49
Obesity-related kidney disease: Beyond hypertension and insulin-resistance
Tarek Ziad Arabi, Areez Shafqat, Belal Nedal Sabbah, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 46
Current and future pharmacotherapies for obesity in children and adolescents
Aaron S. Kelly
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 9, pp. 534-541
Closed Access | Times Cited: 28
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek, László Imre Tóth, Attila Pető, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1320-1320
Open Access | Times Cited: 10
Mediators of Amylin Action in Metabolic Control
Christina N. Boyle, Yi Zheng, Thomas A. Lutz
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2207-2207
Open Access | Times Cited: 33
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Jang Won Son, Soo Lim
Endocrinology and Metabolism (2024) Vol. 39, Iss. 2, pp. 206-221
Open Access | Times Cited: 5
The role of amylin, a gut–brain axis hormone, in metabolic and neurological disorders
Tahir Muhammad, Stephen F. Pastore, Katrina V. Good, et al.
FASEB BioAdvances (2025)
Open Access
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
An update on current type 2 diabetes mellitus (T2DM) druggable targets and drugs targeting them
Prerna Uniyal, Surbhi Panwar, Anuj M. Bhatt, et al.
Molecular Diversity (2025)
Closed Access
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Rikke Viggers, Nicklas H. Rasmussen, Peter Vestergaard
JBMR Plus (2023) Vol. 7, Iss. 11
Open Access | Times Cited: 9
Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long‐acting dual amylin and calcitonin receptor agonist improves insulin‐mediated glycaemic control and controls body weight
Simone Anna Melander, Anna Thorsø Larsen, M.A. Karsdal, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 12, pp. 1829-1842
Closed Access | Times Cited: 3
Hyperglycemia-driven signaling bridges between diabetes and cancer
Somayyeh Ghareghomi, Payam Arghavani, Majid Mahdavi, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116450-116450
Closed Access | Times Cited: 3
Amylin analogs for the treatment of obesity without diabetes: present and future
Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic, et al.
Expert Review of Clinical Pharmacology (2024)
Closed Access | Times Cited: 2
Phytoconstituents of Ashwagandha as potential inhibitors of human islet amyloid polypeptide (hIAPP): an in silico investigation
Nandeshwar, Janmejaya Rout, Smita Manjari Panda, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 20, pp. 11020-11036
Closed Access | Times Cited: 5
An Insight into the Development of Potential Antidiabetic Agents along with their Therapeutic Targets
Siddhita Tiwari, Paranjeet Kaur, Deepali Gupta, et al.
Endocrine Metabolic & Immune Disorders - Drug Targets (2023) Vol. 24, Iss. 1, pp. 50-85
Closed Access | Times Cited: 4
Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs
Elita Yuliantie, Phuc N. H. Trinh, Caroline A. Hick, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116483-116483
Open Access | Times Cited: 1
Pharmacotherapy for chronic obesity management: a look into the future
Mariana Abdel-Malek, Lisa Yang, Alexander D. Miras
Internal and Emergency Medicine (2023) Vol. 18, Iss. 4, pp. 1019-1030
Open Access | Times Cited: 3
G protein-coupled receptors and obesity
Alessandro Pocai
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 3
Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists
Raymond J. Patch, Rui Zhang, Suzanne C. Edavettal, et al.
European Journal of Medicinal Chemistry (2022) Vol. 236, pp. 114330-114330
Closed Access | Times Cited: 3
Identification of Electrostatic Hotspots at the Binding Interface of Amylin and Insulin-Degrading Enzyme: A Structural and Biophysical Investigation
Wei Li
(2024)
Open Access
Identification of Electrostatic Hotspots at the Binding Interface of Amylin and InsulinDegrading Enzyme: A Structural and Biophysical Investigation
Wei Li
Journal of Genetic Engineering and Biotechnology Research (2024) Vol. 6, Iss. 1, pp. 01-16
Open Access
Isoquinoline Small Molecule Ligands are Agonists and Probe-Dependent Allosteric Modulators of the Glucagon Subfamily of Gpcrs
Elita Yuliantie, Phuc N. H. Trinh, Caroline A. Hick, et al.
(2024)
Closed Access
Page 1 - Next Page

Scroll to top